265 related articles for article (PubMed ID: 10889378)
41. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.
Chism DB; Hanlon AL; Horwitz EM; Feigenberg SJ; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):380-5. PubMed ID: 15145151
[TBL] [Abstract][Full Text] [Related]
42. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
43. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
Nguyen KH; Horwitz EM; Hanlon AL; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):377-83. PubMed ID: 12957248
[TBL] [Abstract][Full Text] [Related]
44. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
45. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer.
Defraene G; Van den Bergh L; Al-Mamgani A; Haustermans K; Heemsbergen W; Van den Heuvel F; Lebesque JV
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1233-42. PubMed ID: 21664059
[TBL] [Abstract][Full Text] [Related]
46. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
47. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer.
Martinez AA; Yan D; Lockman D; Brabbins D; Kota K; Sharpe M; Jaffray DA; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1226-34. PubMed ID: 11483333
[TBL] [Abstract][Full Text] [Related]
48. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
Kattan MW; Eastham JA; Wheeler TM; Maru N; Scardino PT; Erbersdobler A; Graefen M; Huland H; Koh H; Shariat S; Slawin KM; Ohori M
J Urol; 2003 Nov; 170(5):1792-7. PubMed ID: 14532778
[TBL] [Abstract][Full Text] [Related]
49. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy.
Symon Z; Griffith KA; McLaughlin PW; Sullivan M; Sandler HM
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):384-90. PubMed ID: 12957249
[TBL] [Abstract][Full Text] [Related]
50. Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh.
Hong L; Alektiar KM; Hunt M; Venkatraman E; Leibel SA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):752-9. PubMed ID: 15183478
[TBL] [Abstract][Full Text] [Related]
51. Role of IMRT in reducing penile doses in dose escalation for prostate cancer.
Sethi A; Mohideen N; Leybovich L; Mulhall J
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):970-8. PubMed ID: 12605975
[TBL] [Abstract][Full Text] [Related]
52. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.
Kestin LL; Goldstein NS; Vicini FA; Mitchell C; Gustafson GS; Stromberg JS; Chen PY; Martinez AA
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):107-18. PubMed ID: 12182980
[TBL] [Abstract][Full Text] [Related]
53. Statistical analysis of dose-volume profiles and its implication for radiation therapy planning in prostate carcinoma.
Vanasek J; Odrazka K; Dolezel M; Kolarova I; Jarkovsky J; Pavlik T; Hlavka A; Dusek L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):769-76. PubMed ID: 23628133
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
Kassim I; Dirkx ML; Heijmen BJ
Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
[TBL] [Abstract][Full Text] [Related]
55. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
Valicenti RK; Winter K; Cox JD; Sandler HM; Bosch W; Vijayakumar S; Michalski J; Purdy J
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):614-20. PubMed ID: 14529764
[TBL] [Abstract][Full Text] [Related]
56. Inclusion of geometric uncertainties in treatment plan evaluation.
van Herk M; Remeijer P; Lebesque JV
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1407-22. PubMed ID: 11955756
[TBL] [Abstract][Full Text] [Related]
57. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
[TBL] [Abstract][Full Text] [Related]
58. A feasibility study of automated inverse treatment planning for cancer of the prostate.
Reinstein LE; Wang XH; Burman CM; Chen Z; Mohan R; Kutcher G; Leibel SA; Fuks Z
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):207-14. PubMed ID: 9422578
[TBL] [Abstract][Full Text] [Related]
59. Spatial and dosimetric evaluation of residual distortions of prostate and seminal vesicle bed after image-guided definitive and postoperative radiotherapy of prostate cancer with endorectal balloon.
Levegrün S; Pöttgen C; Xydis K; Guberina M; Abu Jawad J; Stuschke M
J Appl Clin Med Phys; 2021 Jan; 22(1):226-241. PubMed ID: 33377614
[TBL] [Abstract][Full Text] [Related]
60. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
